The adoption of Risk-Based Quality Management, the process of identifying, monitoring, and mitigating the risks that could impact the quality or safety of a clinical trial, is accelerating. Organizations are benefitting from reduced study timelines, increased efficiency, and enhanced patient safety. Join us on May 20-21, 2021 to discuss how we can continue to leverage RBQM to build safer, more efficient clinical trials of the future.
About
[#RBQMLIVE]
The Virtual Event of '21

Until the day of
the event…
#RBQMLive
[FEATURED SPEAKERS]
Meet the Speakers

Ken Getz
[Professor, Tufts Center for the Study of Drug Development]

Lynne Cesario
[Global Risk-Based Monitoring Program Lead, Pfizer]

Sy Pretorius
[President, Clinical Development and Chief Medical Officer, Parexel]

Jacqueline Gough
[Jacqueline Gough, Director, Central Monitoring, Alexion Pharmaceuticals]

Esther Huffman O’Keefe
[Associate Director - Monitoring, Regeneron Pharmaceuticals]

Mary Arnould
[Director, Astellas Pharma]